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Abstract.
Background:Pittsburgh Compound B (PiB) positron emission tomography (PET) is used to visualize in vivo amyloid plaques
in the brain. Frequently the PiB examinations are complemented with a fluorodeoxyglucose (FDG) PET scan to further assess
neurodegeneration.
Objective: Our goal is to identify alternative correlates of FDG images by assessing which kinetic methods originate PiB
derived relative delivery ratio (R1) images that can be correlated with the FDG images, and to compare them with PiB
perfusion (pPiB) images obtained from the early-phase of PiB acquisition.
Methods: We selected 52 patients with cognitive impairment who underwent a dynamic PiB and FDG acquisitions. To
compute the R1 images, two simplified reference tissue models (SRTM and SRTM2) and two multi-linear reference tissue
models (MRTM and MRTM2) were used. The pPiB images were obtained in two different time intervals.
Results: All six types of images were of good quality and highly correlated with the FDG images (mean voxelwise within-
subjects r > 0.92). The higher correlation was found for FDG-R1(MRTM). Regarding the voxelwise regional correlation, the
higher mean all brain correlations was r = 0.825 for FDG-R1(MRTM) and statistically significant in the whole brain analysis.
Conclusion: All R1 and pPiB images here tested have potential to assess the metabolic impact of neurodegeneration almost
as reliably as the FDG images. However, this is not enough to validate these images for a single-subject analysis compared
with the FDG image, and thus they cannot yet be used clinically to replace the FDG image before such evaluation.
Keywords: Alzheimer’s disease, 11C-PIB, compartmental models, 18F-FDG, neurodegeneration, perfusion
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INTRODUCTION
Positron emission tomography (PET) imaging
with Pittsburgh Compound B (PiB) labeled with 11C
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tracer has been increasingly used in many nuclear
medicine centers to visualize in vivo amyloid plaques
in the brain, which is a core molecular imaging fea-
ture of Alzheimer’s disease (AD) [1]. However, the
presence of high levels of amyloid plaques in the brain
does not directly imply concurrent neural degen-
eration. Thus, regional cerebral blood flow (rCBF)
and regional cerebral glucose metabolism have been
extensively used as indirect biomarkers of synaptic
dysfunction and neurodegeneration. Previous stud-
ies have shown a tight coupling between rCBF and
regional glucose metabolism [2]. This last one has
frequently been assessed with fluorodeoxyglucose
(FDG) labeled with 18F for PET systems.
Frequently, patients with cognitive impairments
for whom a differential diagnosis is difficult to pro-
vide are requested to undergo double PET imaging:
PiB (or other available amyloid tracer, as florbetaben
or florbetapir) and FDG, to help solve such diag-
nostic difficulties. However, this has the potential
drawback of cost and radiation exposure increase.
Complementary surrogate measures that avoid these
problems are therefore worth being investigated. As
a possible alternative, if a dynamic PiB PET acqui-
sition is performed, beyond the parametric binding






be estimated for each brain voxel from pharmacoki-
netic analyses of PiB, thereby providing such type of
alternative (Fig. 1).
A previous study has suggested that there is a sig-
nificant correlation between the FDG images and the
R1 images [3]. Two other studies also have found
a significant correlation between the FDG and the
PiB perfusion (pPiB) images [4, 5]. In addition,
Chen and colleagues [6] showed that the relative
delivery ratio R1 of PiB is highly correlated with
relative rCBF measured by 15O-water normalized to
cerebellum. Other research groups have focused on
these issues using other available markers of amy-
loid plaques. For instance, Daerr et al. [7] showed
a good correlation of early acquisitions of [18F]-
florbetaben (FBB) PET with FDG PET [7], and Lin
et al. [8] showed that Mini-Mental State Examination
(MMSE) scores are significantly associated with the
degree of perfusion impairment as assessed by early
phase of 18F-AV-45 PET on a dataset of patients with
AD, mild cognitive impairment (MCI), and healthy
controls (HC).
Our main goal is to assess which is the best solu-
tion to obtain an image from the PiB PET acquisition
Fig. 1. Two-tissue compartment model with reference region.
CF+NS is the concentration due to free and nonspecific binding,
CS is the concentration due to specific binding.
comparable with the FDG PET image, and thus to
provide a proxy measure of synaptic dysfunction
and neurodegeneration. We considered four mod-
els to obtain the R1 images and two time periods
to obtain the pPiB images. For the R1 images, we
used the simplified reference tissue model (SRTM),
the multi-linear reference tissue model (MRTM), the
SRTM with fixed k′2 (SRTM2), and the MRTM with
fixed k′2 (MRTM2). To generate the pPiB images,
we considered two time periods that have been con-
sidered to be optimal [4, 9, 10], one between 0 and
6 min (pPiB(0–6)) and the other between 1 and 8 min
(pPiB(1–8)). A second goal is to validate the results
obtained by Meyer and colleagues [3] but now using
a different and larger dataset of patients.
MATERIALS AND METHODS
Patients
A total of 52 patients who underwent 11C-PiB
PET and 18F-FDG PET examinations were included
in this study. We included all patients from Insti-
tute of Nuclear Science Applied to Health (ICNAS,
University of Coimbra), except patients with head
movements during the acquisitions above the scanner
resolution. All patients gave written informed con-
sent, as approved by the Ethics committee of the
University of Coimbra. Demographic and clinical
information are summarized in Table 1. The criteria
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Table 1
Synthesis of clinical and demographic data of the patients
Subjects Number of Age Amyloid burden
patients (M/F) (mean ± SD) negative / low / high
AD 20 (6/14) 68 ± 6 1 / 0 / 19
MCI 19 (8/11) 69 ± 7 6 / 7 / 6
PPA 5 (3/2) 66 ± 7 2 / 0 / 3
FTD 4 (1/3) 72 ± 10 3 / 1 / 0
Other 4 (1/3) 54 ± 10 4 / 0 / 0
Total 52 (19/33) 67 ± 8 16 / 8 / 28
for the diagnosis of the neurodegenerative disorders
were: probable AD dementia according to NINCDS-
ADRDA criteria [11], MCI due to AD following the
NINCDS-ADRDA criteria [12], primary progressive
aphasia according to the recommendations of Gorno-
Tempini and colleagues [13], and the behavioral
variant of frontotemporal dementia (FTD) according
to the criteria of the International Behavioural Variant
FTD Criteria Consortium [14].
We also categorized PiB-PET images in three
groups—amyloid negative, amyloid borderline/low
burden, and high amyloid deposition—following our
local classifier based on support vector machines
(SVM), which uses the voxelwise brain grey matter
standardized uptake value ratio (SUVR) computed
from the PiB-PET images, and using the cerebellar
grey matter as reference region.
PET acquisitions
All 11C-PIB PET and 18F-FDG PET acquisitions
were performed in the same scanner (Philips PET/CT
Gemini GXL), preceded by a low-dose brain CT
acquisition for attenuation correction. Except for one
patient, both scans were acquired on the same day
(18F-FDG was injected approximately 2 h after 11C-
PiB injection). For each acquisition, the patient’s head
was restrained with a soft elastic tape. All patients
fasted for at least 6 h before 18F-FDG injection.
The 11C-PiB PET acquisitions were dynamic,
lasted for 90 min (37 frames: 4 × 15 s + 8 × 30 s +
9 × 60 s + 2 × 180 s + 14 × 300 s) and started imme-
diately after the intravenous bolus injection of
approximately 555 MBq of 11C-PiB. The 18F-FDG
PET acquisitions were static, started approximately
30 min after the intravenous bolus injection of
approximately 185 MBq of 18F-FDG and lasted for
30 min.
Both acquisitions were reconstructed using the
LOR RAMLA algorithm (Philips PET/CT Gemini
GXL) with attenuation and scatter correction. In both
cases, an isotropic voxel size of 2 mm was defined.
Quantiﬁcation of pPiB images and relative
delivery ratio R1 parametric images
Voxelwise pPiB(0–6 min) and pPiB(1–8 min)
images were computed by cumulatively adding the
frames in the time periods between 0 and 6 min and
between 1 and 8 min after injection, respectively.
These time intervals where chosen since they were
found optimal in previous works.
Four different approaches were used for quantifi-
cation of relative delivery ratio R1: MRTM, SRTM,
MRTM2 and SRTM2. For all four methods, the cere-
bellar grey matter was used as reference region. This
choice is based on the work of Thal et al. [15] where
the authors showed that there is no amyloid deposi-
tion in the cerebellar grey matter before the phase 5
(advanced cases) and even in this phase the deposi-
tion is very small. This was confirmed using PiB PET
by Klunk et al. [16].
SRTM and SRTM2
We implemented the SRTM [17] method using
basis functions [18], since this solution is more sta-
ble than non-linear least squares method at the voxel
level. The simplified operational equation is
C(t) = θ1C′ (t) + θ2C(t) ⊗ e−θst
where C is the concentration in the target region, C′ is
the concentration in the reference region and ⊗ is the
convolution operator. We have considered 200 values
for θ3 between 0.017 min–1 and 0.137 min–1 and,
for each θ3, the other two parameters were estimated
using linear least squares.
The SRTM2 is based on SRTM but implemented in
two steps [19]. In the first one, the SRTM is applied to
compute the BPND, R1 and k2 at the voxel level [18].
Then, k′2 is derived as k
′
2 = (BPND − 1)k2/R1. Since
k
′
2 should be the same for all brain voxels, it is esti-
mated by computing the median of all k′2 obtained.
Then, in the second step, it is fixed and the equation is
rearranged, with only two parameters remaining to be
optimized [19]. As for the SRTM, we implemented
SRTM2 using basis functions and the same range of
values for θ3. Since k
′
2 estimation is very sensitive
to noise when computed at the voxel level, to com-
pute it in the first step we have resampled the original
dynamic images with voxels of 8 × 8 × 8 mm3 and
only considered the values of k′2 when 0 < BPND < 3,
k2 > 0 and R1 > 0.
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MRTM and MRTM2
The MRTM implemented is based on the fol-
lowing multi-linear reference tissue model equation
[20]:


















, γ2 = 1b , γ3 = − V(V ′k′2b) . It can be done effi-







, k2 = −γ2 and R1 = γ3. In the exper-
imental analysis we did, very noisy BPND images
were obtained simultaneously with negative values
of k2. Thus, we constrained the k2 as a minimum
of 0.012 min–1. This value was established experi-
mentally based on the observation of the values of
k2 obtained in a subset of the images considering 10
regions of interest (anterior cingulate, caudate, mesial
temporal cortex, prefrontal cortex, posterior cingu-
late, putamen, precuneus, occipital cortex, parietal
superior, and inferior cortex).
MRTM2 is a two-step implementation of the
MRTM [20]. In the first step, the median of k′2 is
estimated using MRTM and then fixed in the second
step. By fixing k′2, the equation can be rearranged to
the following































and k2 = −γ2.
Implementation of algorithms
For the computation of the R1 and pPiB images, in
the initial step a sum image was built using all frames
and then the sum image was registered to the Montreal
Neurological Institute (MNI) space using in-house
made software using a deformable model based on
cubic B-splines and a PiB sum image template as
reference image. Next, all frames of the dynamic
image were also registered using the same geometric
transformation. Image registration algorithms were
implemented using the Insight Toolkit (ITK) software
library, version 3.20, and based on the optimization
of the mutual information similarity measure [21].
Parameter optimization was done using the Vision
Numerics Library (VNL) available in the ITK [21].
The sum PiB template is in the MNI space and was
built in our institution using a set of normal PiB scans
and with the help of the MRI of the subjects.
18F-FDG image processing
The 18F-FDG images were first rigidly registered
with the correspondent R1(MRTM) image and then
registered to the MNI space using the transforma-
tion found when the respective 11C-PiB images were
registered to the MNI space.
Statistics
Intensity normalization
The pPiB, R1 and 18F-FDG registered images
were smoothed with a Gaussian kernel with 8 mm
full width at half maximum and then intensity
normalized. The intensity normalization was done
independently per each image by dividing each voxel
value by the mean brain values of the respective
image. The brain voxels were defined based on the
MNI template.
Within-subjects correlation
For each subject, the mean Pearson correlation
coefficients between the pairs FDG-pPiB(0–6 min),
FDG-pPiB(1–8 min), FDG-R1(MRTM), FDG-R1
(MRTM2), FDG-R1(SRTM), and FDG-R1(SRTM2)
were computed. For each FDG image, all brain vox-
els were correlated with the correspondent voxels of
the pPiB or R1 image, yielding a correlation coeffi-
cient per pair of images per subject. Comparison of
correlations was performed using repeated measures
ANOVA.
To assess differences of the correlation among the
amyloid burden groups (negative, low and high) the
Kruskal-Wallis test was used. ANOVA and Kruskal-
Wallis test were performed using the Statistical
Package for the Social Sciences (SPSS, v20).
Voxelwise regional correlation
Since variations of cerebral blood flow and glucose
metabolism coupling are not homogeneous across all
brain regions [22], we assessed the regional corre-
lation at voxel level. Per each voxel location, we
computed the correlation between the group of the
FDG images against the groups of pPiB or R1 images.
Thus, we obtained the whole-brain correlation distri-
bution.
Correlation significance was assessed per each
voxel using Benjamini-Hochberg false discovery
rate (FDR) correction for multiple comparisons
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Fig. 2. Boxplot graph comparing the within subjects correla-
tion coefficient between the FDG images and the R1(SRTM),
R1(SRTM2), R1(MRTM), R1(MRTM2), pPiB(0–6min) and
pPiB(1–8min) images.
with = 0.05. Differences in the mean whole




Results of the Pearson linear correlation coef-
ficient between FDG, R1 and pPiB images are
shown in Fig. 2. Mean ± standard deviation values
were 0.929 ± 0.016, 0.924 ± 0.020, 0.936 ± 0.015,
0.933 ± 0.016, 0.933 ± 0.016, and 0.932 ± 0.018,
for the correlations FDG-R1(SRTM), FDG-
R1(SRTM2), FDG-R1(MRTM), FDG-R1(MRTM2),
FDG-pPiB(0–6 min), and FDG-pPiB(1–8 min),
respectively. This means that the R1 and pPiB
Fig. 3. Two examples of the FDG, pPiB(1–8min), and R1(MRTM) images, respectively from the left to the right. The images on the top are
from a patient with AD, and on the bottom from a patient with FTD. In the top there is an asymmetric uptake in the parietal cortex and on
the bottom an asymmetric uptake in the frontal cortex. These patterns can be seen in the three types of images.
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Table 2
Voxelwise regional Pearson correlation coefficient between the
FDG and R1 or pPiB images
Images Median Mean ± SD Range (min – max)
R1(SRTM) 0.826 0.809 ± 0.093 0.247–0.972
R1(SRTM2) 0.819 0.802 ± 0.097 0.194–0.977
R1(MRTM) 0.841 0.825 ± 0.090 0.345–0.981
R1(MRTM2) 0.838 0.820 ± 0.094 0.267–0.980
pPiB(0–6min) 0.827 0.809 ± 0.097 0.276–0.984
pPiB(1–8min) 0.838 0.817 ± 0.097 0.285–0.981
images can explain about 85% of the content of
the FDG images. Figure 3 shows two examples of
the FDG, pPiB(1–8 min), and R1(MRTM) images
of two patients where it is easy to visually identify
asymmetric uptake, which very likely indicates
hypometabolism in region with lower FDG, R1 and
pPiB values.
Repeated measures ANOVA with Greenhouse-
Geisser correction shows that there is a statistically
significant difference (F = 23.359, p < 0.001) among
the correlation coefficients. Based on post hoc paired
t-test with Bonferroni correction for multiple compar-
isons, it was observed that the correlation between the
FDG and R1(MRTM) images is significantly higher
(p < 0.004) than the other correlations. Although sta-
tistically significant differences have been found
among the mean computed correlations, the differ-
ences are low and with likely irrelevant biologically
significance (lesser than 0.012).
There is not a statistically significant difference in
the correlation between groups of patients, amyloid
positive, amyloid doubtful or amyloid negative, per
any type of images (Kruskal-Wallis test, p≥ 0.180),
suggesting that their biological correlates remain the
same across groups.
Voxelwise regional correlation
A summary of the results for all brain voxels
Pearson correlation coefficients is shown in Table 2.
Voxelwise correlations between FDG and R1 or pPiB
were statistically significant in all brain voxels, except
for the R1(SRTM2) where it was nevertheless sig-
nificant in more than 99.9% of the brain voxels.
There is a statistically significant difference among
the mean voxelwise whole-brain magnitude of cor-
relations between the six types of images; however
the difference of the mean is very low (maximum
difference of the mean is 0.023). As can be seen in
Table 2, the median of the Pearson correlation coeffi-
cient is higher than 0.81, which means the correlation
is strong or very strong in most of the brain voxels,
irrespective of the particular model, suggesting that
this proxy-based approach is relatively model inde-
pendent.
Figure 4 shows the voxelwise correlation between
the FDG images and the correspondent set of
R1(MRTM) images. As can be seen, the correlation
is strong or very strong (r≥ 0.7) in most of the brain.
The regions where the correlation is not as robust
are mainly in the transition between the grey and
white matter. The distributions of the brain corre-
lation between the FDG and the other R1 or pPiB
images are similar.
DISCUSSION
In this work we performed a voxelwise analy-
sis of the correlation between the FDG-PET images
with the R1 or pPiB images computed from PiB-
PET dynamic acquisitions. Results show a very
high (r > 0.9) mean within-subject Pearson correla-
tion coefficient of the FDG images with the pPiB
and R1 images. A significantly higher correlation was
found for the FDG-R1(MRTM) against the correla-
tion of the other pairs, however the difference had
a very small effect size, and is therefore of likely
irrelevant biological significance.
A previous study, Meyer et al. [3], also studied
the correlation between R1-PiB and FDG images,
but using only the SRTM2 kinetic model and a
small dataset of 22 patients, while we tested four
kinetic models for the computation of the R1 and
used a dataset of 52 patients. Moreover, we fur-
ther computed the correlation between the FDG and
pPiB images using two time intervals and com-
pared them with the correlation obtained between
the R1 and FDG images. They found a slightly
inferior within-subject correlation of approximately
r = 0.79 between the FDG and R1 generated by the
SRTM2 [19], using a similar protocol acquisition. We
think there are two main reasons that may explain
our superior results. First, different datasets were
used; second, the implementation of the algorithms,
both the kinetic models and the image processing.
As in Meyer et al. [3], we did not find a statisti-
cally significant difference in the correlation among
groups of patients (amyloid negative versus amy-
loid borderline versus high amyloid deposition) for
the R1 images. The same occurred for the pPiB
images, suggesting that the use of these proxy mea-
sures is robust and independent of the used analysis
method.
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Fig. 4. Mean voxelwise correlation between the set of FDG images and the correspondent set of R1(MRTM) images. The correlation image
is overlapping the template MRI image.
Regarding the regional voxelwise correlation of
the FDG images with the pPiB and R1 images, a
high median voxelwise correlation was found for
the six types of images (r≥ 0.82). The regions with
lesser correlation are mostly in the border between the
grey and white matter. We think this can be partially
explained by the image registration imperfections,
since the uptake difference is higher from the grey
matter to the white matter than within the grey matter
or white matter.
We have opted to use the R1, pPiB and FDG
images after intensity normalization since the stan-
dardized uptake value (SUV) of the FDG images
are highly dependent on the several factors that are
not related to the cerebral glucose metabolism, for
instance, the blood glucose levels, insulin levels or
anemia; and the R1 images depend on the free and
non-specific binding in the cerebellar grey matter of
each patient. Thus, after intensity normalization the
variability of the uptake due to brain external factors
is reduced, which is important for the computation
of the voxelwise regional correlation. However, it is
important to stress out that this normalization has no
influence in the within-subject correlation, since the
correlation is independent on scale factors.
In clinical practice, the R1 and pPiB images should
not be normalized, neither spatially nor intensity. The
spatial normalization may introduce distortions that
difficult the clinical analysis and the SUV of the pPiB
images may have clinical implications.
In a previous study, the SRTM2 and the MRTM2
methods were found as the best options to com-
pute the BPND for clinical studies [23]. These two
methods have shown to be less affected by noise,
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producing BPND images with better contrast than
the images obtained from the other tested methods,
and also because they provided the best accuracies
in simulated studies. In our implementation, SRTM2
and MRTM2 originated BPND images with less
noise than the SRTM and MRTM methods, respec-
tively; however, the R1 images had higher level of
noise.
Intriguingly, SRTM and MRTM originated bet-
ter quality R1 images than their two steps version
SRTM2 and MRTM2, respectively. This was not
expected, since SRTM2 and MRTM2 have been used
in previous studies and have originated high quality
R1 and BPND images [3, 6, 23]. In fact, in our imple-
mentation, the BPND obtained using the SRTM2 and
MRTM2 are of better quality than the BPND obtained
using the SRTM and MRTM, however the same did
not happen for the R1 parametric images.
In terms of pPiB images, our results are as
expected, since they confirm previous works where a
significant correlation between the FDG and the PiB
perfusion (pPiB) images was found [4, 5].
We have shown that there is high whole-brain
within-subject correlation between R1 or pPiB and
FDG measures (Fig. 2), however this is not enough
to validate the R1 or pPiB images for a single-subject
analysis compared with the FDG image [24], and
thus these images cannot be used clinically to replace
the FDG image before such evaluation. Other limita-
tion of this study is that we cannot ascertain that the
small differences found between the normalized R1 or
pPiB images and the normalized FDG images do not
hide some information related with neuronal injury.
In any case, the work of Lin et al. [8] showed that the
MMSE scores are significantly associated with the
degree of perfusion impairment, which we believe is
solid evidence for the usefulness of the R1 and pPiB
images.
In conclusion, the results show that both R1 and
pPiB images can explain about 85% of the con-
tent of the FDG images, and thus they may be of
great importance to assess the synaptic dysfunction
and neurodegeneration when the FDG images are
not available. The higher correlation with the FDG
images was found for the R1(MRTM). However, the
differences for the others R1 and pPiB images are
rather small.
The pPiB images have originated results which are
very close to the best R1 images and are easier to
compute, with shorter acquisition time. Thus they are
probably the best choice to be computed routinely in
the busy nuclear medicine centers. On the other hand,
in centers where the BPND images are computed for
helping in the differential diagnosis, the R1 images
may be the best choice, since they can be obtained
simultaneously with the BPND images.
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